| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Whooping Cough | 15 | 2023 | 60 | 5.630 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 11 | 2023 | 35 | 4.590 |
Why?
|
| Vaccination | 18 | 2025 | 1011 | 2.960 |
Why?
|
| Diphtheria | 4 | 2023 | 16 | 2.310 |
Why?
|
| Immunization | 7 | 2014 | 315 | 1.840 |
Why?
|
| Tetanus | 4 | 2020 | 27 | 1.760 |
Why?
|
| Immunity, Maternally-Acquired | 6 | 2013 | 35 | 1.740 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 894 | 1.560 |
Why?
|
| Influenza Vaccines | 3 | 2024 | 491 | 1.300 |
Why?
|
| Vaccines | 6 | 2023 | 378 | 1.180 |
Why?
|
| Antibodies, Bacterial | 5 | 2023 | 404 | 1.110 |
Why?
|
| Papillomavirus Vaccines | 3 | 2023 | 106 | 1.050 |
Why?
|
| Pertussis Toxin | 3 | 2023 | 29 | 1.040 |
Why?
|
| Pregnancy | 21 | 2024 | 7512 | 1.010 |
Why?
|
| Hepatitis B | 3 | 2015 | 172 | 1.000 |
Why?
|
| Hepatitis B Vaccines | 3 | 2015 | 45 | 0.970 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2021 | 484 | 0.930 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 471 | 0.920 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2023 | 69 | 0.880 |
Why?
|
| Infant, Newborn | 23 | 2021 | 8574 | 0.880 |
Why?
|
| Hepatitis B virus | 2 | 2015 | 142 | 0.870 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2023 | 366 | 0.850 |
Why?
|
| Pertussis Vaccine | 4 | 2023 | 25 | 0.840 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 398 | 0.830 |
Why?
|
| Influenza in Birds | 1 | 2023 | 29 | 0.830 |
Why?
|
| Fluconazole | 3 | 2009 | 50 | 0.830 |
Why?
|
| Transplant Recipients | 2 | 2015 | 225 | 0.820 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 1 | 2023 | 30 | 0.820 |
Why?
|
| Candidiasis | 3 | 2009 | 138 | 0.760 |
Why?
|
| Influenza, Human | 2 | 2024 | 691 | 0.750 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2012 | 42 | 0.740 |
Why?
|
| Health Personnel | 3 | 2015 | 538 | 0.700 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2021 | 253 | 0.670 |
Why?
|
| Immunization Programs | 2 | 2011 | 65 | 0.640 |
Why?
|
| Humans | 70 | 2025 | 133858 | 0.620 |
Why?
|
| Antiviral Agents | 1 | 2024 | 822 | 0.600 |
Why?
|
| Parents | 6 | 2024 | 1058 | 0.600 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 573 | 0.590 |
Why?
|
| Female | 42 | 2025 | 71588 | 0.570 |
Why?
|
| Meningococcal Infections | 4 | 2008 | 20 | 0.550 |
Why?
|
| Antifungal Agents | 4 | 2018 | 309 | 0.550 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2009 | 128 | 0.540 |
Why?
|
| Adult | 30 | 2025 | 31926 | 0.540 |
Why?
|
| Texas | 11 | 2015 | 3684 | 0.530 |
Why?
|
| Decision Making | 4 | 2015 | 696 | 0.530 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2012 | 327 | 0.530 |
Why?
|
| Infant | 18 | 2024 | 13135 | 0.520 |
Why?
|
| Adolescent | 26 | 2023 | 20517 | 0.500 |
Why?
|
| Liver Transplantation | 2 | 2015 | 1125 | 0.500 |
Why?
|
| Bacteremia | 3 | 2012 | 417 | 0.490 |
Why?
|
| Postpartum Period | 4 | 2014 | 227 | 0.480 |
Why?
|
| Child | 22 | 2025 | 25712 | 0.470 |
Why?
|
| Young Adult | 15 | 2023 | 9883 | 0.450 |
Why?
|
| Coagulase | 2 | 2012 | 23 | 0.450 |
Why?
|
| Staphylococcus | 2 | 2012 | 68 | 0.440 |
Why?
|
| Streptococcal Infections | 2 | 2022 | 248 | 0.400 |
Why?
|
| Behavior Therapy | 1 | 2014 | 268 | 0.380 |
Why?
|
| Equipment Contamination | 1 | 2012 | 40 | 0.380 |
Why?
|
| Culture Media | 1 | 2012 | 184 | 0.370 |
Why?
|
| Viral Load | 2 | 2024 | 412 | 0.360 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 176 | 0.360 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2022 | 114 | 0.350 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 135 | 0.340 |
Why?
|
| Virus Diseases | 1 | 2013 | 289 | 0.340 |
Why?
|
| Bacterial Infections | 1 | 2013 | 325 | 0.330 |
Why?
|
| Meningococcal Vaccines | 2 | 2012 | 30 | 0.330 |
Why?
|
| Cross Infection | 1 | 2012 | 332 | 0.300 |
Why?
|
| Male | 29 | 2025 | 65821 | 0.290 |
Why?
|
| Meningitis, Haemophilus | 1 | 2007 | 34 | 0.280 |
Why?
|
| Candida albicans | 1 | 2008 | 90 | 0.280 |
Why?
|
| Family Health | 1 | 2008 | 267 | 0.280 |
Why?
|
| Middle Aged | 15 | 2025 | 29378 | 0.270 |
Why?
|
| Mycoses | 1 | 2008 | 121 | 0.270 |
Why?
|
| Communication | 1 | 2011 | 541 | 0.260 |
Why?
|
| Hepatitis C | 2 | 2001 | 388 | 0.260 |
Why?
|
| Child, Preschool | 7 | 2024 | 14776 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 1201 | 0.240 |
Why?
|
| United States | 8 | 2025 | 11681 | 0.230 |
Why?
|
| Measles | 1 | 2025 | 44 | 0.230 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2004 | 24 | 0.230 |
Why?
|
| Caregivers | 2 | 2024 | 585 | 0.230 |
Why?
|
| Fimbriae Proteins | 1 | 2004 | 22 | 0.230 |
Why?
|
| Bordetella pertussis | 1 | 2004 | 16 | 0.230 |
Why?
|
| Hemagglutinins | 1 | 2004 | 25 | 0.230 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 118 | 0.220 |
Why?
|
| Adhesins, Bacterial | 1 | 2004 | 76 | 0.220 |
Why?
|
| Child, Hospitalized | 1 | 2024 | 76 | 0.220 |
Why?
|
| Nasopharynx | 1 | 2024 | 86 | 0.220 |
Why?
|
| Research Design | 2 | 2025 | 754 | 0.210 |
Why?
|
| Frontal Sinusitis | 1 | 2002 | 4 | 0.200 |
Why?
|
| Breast Feeding | 1 | 2024 | 243 | 0.200 |
Why?
|
| Gestational Age | 3 | 2018 | 1215 | 0.200 |
Why?
|
| Lymphadenitis | 1 | 2022 | 26 | 0.200 |
Why?
|
| Epidural Abscess | 1 | 2002 | 11 | 0.200 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 1204 | 0.190 |
Why?
|
| Kinetics | 2 | 2020 | 1354 | 0.190 |
Why?
|
| Infant, Premature, Diseases | 1 | 2004 | 255 | 0.190 |
Why?
|
| Incidence | 6 | 2021 | 3393 | 0.190 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 476 | 0.180 |
Why?
|
| Papillomaviridae | 1 | 2022 | 189 | 0.170 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2018 | 123 | 0.170 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2009 | 178 | 0.170 |
Why?
|
| Vaccines, Acellular | 1 | 2020 | 5 | 0.170 |
Why?
|
| England | 1 | 2020 | 73 | 0.160 |
Why?
|
| Sepsis | 1 | 2004 | 516 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2022 | 407 | 0.160 |
Why?
|
| Risk Factors | 5 | 2015 | 11077 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 866 | 0.160 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2015 | 54 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3740 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2022 | 403 | 0.150 |
Why?
|
| Ireland | 4 | 2003 | 34 | 0.150 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 18 | 0.150 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 79 | 0.140 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 330 | 0.140 |
Why?
|
| Streptococcus agalactiae | 2 | 2022 | 103 | 0.140 |
Why?
|
| Mothers | 1 | 2020 | 369 | 0.140 |
Why?
|
| Logistic Models | 2 | 2015 | 1908 | 0.130 |
Why?
|
| Single-Blind Method | 3 | 2021 | 251 | 0.130 |
Why?
|
| Basophils | 1 | 2016 | 14 | 0.130 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2016 | 21 | 0.130 |
Why?
|
| Prenatal Diagnosis | 1 | 2001 | 627 | 0.130 |
Why?
|
| Cell Degranulation | 1 | 2016 | 31 | 0.130 |
Why?
|
| Exanthema | 1 | 2017 | 71 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 304 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2008 | 5173 | 0.130 |
Why?
|
| Mast Cells | 1 | 2016 | 83 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 823 | 0.120 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2015 | 10 | 0.120 |
Why?
|
| Itraconazole | 1 | 2015 | 25 | 0.120 |
Why?
|
| Histoplasma | 1 | 2015 | 32 | 0.120 |
Why?
|
| Cushing Syndrome | 1 | 2015 | 22 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2015 | 19 | 0.120 |
Why?
|
| Budesonide | 1 | 2015 | 21 | 0.120 |
Why?
|
| Bronchiectasis | 1 | 2015 | 21 | 0.120 |
Why?
|
| Culture | 1 | 2015 | 73 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2015 | 50 | 0.120 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 108 | 0.120 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2014 | 15 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 265 | 0.110 |
Why?
|
| Skin | 1 | 2017 | 551 | 0.110 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 240 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 382 | 0.100 |
Why?
|
| Time Factors | 2 | 2015 | 6583 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 293 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 1490 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2023 | 244 | 0.100 |
Why?
|
| Haemophilus Vaccines | 1 | 2012 | 30 | 0.100 |
Why?
|
| Streptococcal Vaccines | 1 | 2012 | 18 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3638 | 0.100 |
Why?
|
| Tetanus Toxoid | 1 | 2012 | 48 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1667 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 397 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 809 | 0.090 |
Why?
|
| Patient Acuity | 2 | 2021 | 68 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2018 | 6654 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1976 | 0.090 |
Why?
|
| Aged | 6 | 2024 | 21722 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 172 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 462 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 89 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 402 | 0.090 |
Why?
|
| Research | 1 | 2012 | 272 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3987 | 0.080 |
Why?
|
| Developing Countries | 1 | 2012 | 288 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5505 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1069 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 184 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2012 | 17460 | 0.080 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2008 | 5 | 0.070 |
Why?
|
| Thyroglossal Cyst | 1 | 2008 | 5 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 494 | 0.070 |
Why?
|
| Recurrence | 1 | 2012 | 1467 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 2975 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 2655 | 0.070 |
Why?
|
| Hospitals | 1 | 2011 | 429 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 335 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2022 | 13010 | 0.070 |
Why?
|
| Liver | 1 | 2015 | 1867 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2023 | 2902 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 3025 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 141 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1188 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 3064 | 0.060 |
Why?
|
| Tennessee | 1 | 2006 | 36 | 0.060 |
Why?
|
| Maternal Age | 1 | 2006 | 139 | 0.060 |
Why?
|
| Measles Vaccine | 1 | 2025 | 13 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1196 | 0.060 |
Why?
|
| Neisseria meningitidis, Serogroup B | 1 | 2005 | 7 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 376 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 827 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 151 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 51 | 0.060 |
Why?
|
| Vaccines, Conjugate | 1 | 2005 | 82 | 0.060 |
Why?
|
| Gentamicins | 1 | 2004 | 96 | 0.060 |
Why?
|
| Cytokines | 2 | 2016 | 1396 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 3 | 2008 | 2515 | 0.050 |
Why?
|
| Animals | 2 | 2023 | 36364 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 142 | 0.050 |
Why?
|
| Information Seeking Behavior | 1 | 2023 | 16 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2004 | 179 | 0.050 |
Why?
|
| Age of Onset | 1 | 2004 | 635 | 0.050 |
Why?
|
| Hypoxia | 1 | 2004 | 262 | 0.050 |
Why?
|
| Hypotension | 1 | 2004 | 191 | 0.050 |
Why?
|
| Survival Rate | 1 | 2008 | 2207 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 247 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 290 | 0.050 |
Why?
|
| Vancomycin | 1 | 2004 | 236 | 0.050 |
Why?
|
| Cellulitis | 1 | 2022 | 63 | 0.050 |
Why?
|
| Patient Selection | 1 | 2006 | 734 | 0.050 |
Why?
|
| Serotyping | 1 | 2002 | 178 | 0.050 |
Why?
|
| Craniotomy | 1 | 2002 | 109 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 66 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 190 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 111 | 0.040 |
Why?
|
| Carrier State | 1 | 2001 | 77 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 198 | 0.040 |
Why?
|
| Zidovudine | 1 | 2000 | 23 | 0.040 |
Why?
|
| Lamivudine | 1 | 2000 | 27 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 896 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2000 | 145 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 36 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 604 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1165 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2004 | 858 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 204 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 35 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 36 | 0.040 |
Why?
|
| Health Policy | 1 | 2001 | 232 | 0.040 |
Why?
|
| Delivery, Obstetric | 1 | 2001 | 258 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1197 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 93 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2008 | 3691 | 0.040 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 344 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 201 | 0.030 |
Why?
|
| Interleukin-33 | 1 | 2016 | 18 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2001 | 1485 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2016 | 52 | 0.030 |
Why?
|
| HIV-1 | 1 | 2000 | 488 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 679 | 0.030 |
Why?
|
| Chimerism | 1 | 2015 | 29 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 251 | 0.030 |
Why?
|
| Mass Screening | 1 | 2001 | 832 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 136 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 261 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2197 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 836 | 0.030 |
Why?
|
| Phenotype | 1 | 2003 | 4532 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 1079 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2014 | 278 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 414 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 1439 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 569 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 1694 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 7204 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 287 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2837 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 1126 | 0.020 |
Why?
|
| Neisseria meningitidis | 1 | 2008 | 20 | 0.020 |
Why?
|
| Cefotaxime | 1 | 2008 | 38 | 0.020 |
Why?
|
| HIV Infections | 1 | 2000 | 2066 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 48 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 2003 | 43 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 153 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 146 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2003 | 57 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 671 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 191 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 778 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 453 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 707 | 0.010 |
Why?
|
| Nelfinavir | 1 | 2000 | 4 | 0.010 |
Why?
|
| Indinavir | 1 | 2000 | 5 | 0.010 |
Why?
|
| Saquinavir | 1 | 2000 | 5 | 0.010 |
Why?
|
| Nevirapine | 1 | 2000 | 16 | 0.010 |
Why?
|
| Ritonavir | 1 | 2000 | 48 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 18881 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 2292 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 2807 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 624 | 0.010 |
Why?
|